RTOG-1010

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Principal Investigator

Howard Safran

Status

Disease Site

Gastrointestinal [GI] Esophageal

Phase

III

Developmental Therapeutics

No

Primary Objective

To determine if trastuzumab increases disease-free survival when combined with trimodality treatment (radiation plus chemotherapy followed by surgery) for patients with HER2-overexpressing esophageal adenocarcinoma

Patient Population

Pathologically confirmed HER2 expressing adenocarcinoma of the esophagus centrally assessed within 56 days prior to Step 2 registration; primary adenocarcinoma of the esophagus involving the mid (up to 25 cm), distal and/or esophagogastric junction. 

Target Accrual

197